Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RAPP
RAPPORT THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$45.77
▼ DOWN 3.95% (-1.88)

KEY STATISTICS

Market Cap$2.19 B
52w High$52.93
52w Low$22.06
Dividend Yield—
Frequency—
P/E-15.06
Volume279.88K
Shares Out.47.83M

COMPANY

LEADERSHIP

Abraham N. Ceesay
CHIEF EXECUTIVE
Abraham N. Ceesay

COMPENSATION 2026

Salary$652,927
Stock Awards$0
Incentive Plan Pay$431,059
All Other Comp.$24,772
Total$6,265,174

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 7, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
84

PRICE TARGET

Target High$75.00
Target Low$52.00
Target Median$65.00
Target Consensus$62.80

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$45.77 ▼ DOWN 3.95% (−$1.88)
$45.75$46.50$47.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM45.77

About Rapport Therapeutics, Inc. Common Stock

https://www.rapportrx.com ↗

Rapport Therapeutics, a Boston-based clinical-stage biopharma founded in 2022, develops small molecule medicines targeting CNS disorders, including RAP-219 for epilepsy and pain, and nAChR programs for pain and hearing conditions.

INDUSTRY

Biotechnology

A PRODUCT RAPPORT THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

RAP-219
RAP-219

RAP-219, Rapport Therapeutics' lead clinical-stage small molecule, targets TARPγ8 to modulate AMPA receptors for treating drug-resistant focal seizures, with Phase 3 trials planned for Q2 2026.

COMPETITORS

COMPETITOR
JAZZ COMPARE
PRAX COMPARE
XENE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
118
LISTED HERE
22
RANKED BY POSITION SIZE
VTI
0.00% · 986.7K
IWM
0.05% · 786.0K
XPH
1.62% · 210.1K
SCHA
0.03% · 136.9K
DFAS
0.03% · 110.1K
SBIO
1.22% · 65.9K
AVSC
0.09% · 59.8K
DWAS
0.57% · 52.4K
XRS2.F
0.05% · 28.5K
NUSC
0.09% · 26.4K
ONEQ
0.01% · 15.9K
OP
OPTZ
0.27% · 15.0K
RSSL
0.04% · 14.7K
BBC
0.77% · 8.2K
GSSC
0.03% · 6.0K
PILL
1.10% · 5.3K
RFLR
0.11% · 2.3K
BIB
0.08% · 1.7K
MNTL
0.21% · 1.5K
ESSC
0.20% · 1.5K
TNXT
0.12% · 485
USFMDN.MX
0.00% · 124

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.70%
HOLDERS
199
TOP 12 OF 199 · RANKED BY POSITION SIZE
Fmr LLC
7.2M sh · $298.89M
Trv Gp V, LLC
7.1M sh · $216.48M
Arch Venture Management, LLC
3.7M sh · $110.74M
Capital International Investors
3.4M sh · $101.06M
Cormorant Asset Management, LP
3.2M sh · $94.82M
Goldman Sachs Group Inc
3.0M sh · $91.08M
Blackrock, Inc.
2.7M sh · $112.5M
Sofinnova Investments, Inc.
1.9M sh · $57.84M
Vanguard Group Inc
1.8M sh · $55.15M
Johnson & Johnson
1.8M sh · $74.36M
Polar Capital Holdings Plc
1.6M sh · $51.39M
Baker Bros. Advisors LP
1.5M sh · $45.95M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF DEVELOPMENT OFFICER
Yeleswaram Krishnaswamy
Sale · 16.2K shares
2026-08-25
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Ceesay Abraham
Sale · 18.9K shares
2026-08-25
★
OFFICER: CHIEF DEVELOPMENT OFFICER
Yeleswaram Krishnaswamy
Sale · 13.2K shares
2026-08-24
★
OFFICER: CHIEF DEVELOPMENT OFFICER
Yeleswaram Krishnaswamy
Sale · 20.8K shares
2026-08-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 1
MARKET OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
BTIG BUY HC Wainwright & Co. BUY Wells Fargo OVERWEIGHT Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
NRIX$26.14COMPARE
KOD$35.36COMPARE
URGN$44.09COMPARE
XNCR$26.61COMPARE
ANAB$56.80COMPARE
SEPN$36.75COMPARE
PHAT$9.50COMPARE
BBOT$8.98COMPARE